Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrea Necchi, Patrizia Giannatempo, Luigi Mariani, Emanuela Fina, Nicola Nicolai, Marzia Pennati, Nadia Zaffaroni, Elena Farè, Luigi Piva, Davide Biasoni, Mario Catanzaro, Tullio Torelli, Silvia Stagni, Massimo Maffezzini, Maurizio Colecchia, Biagio Paolini, Vera Cappelletti, Maria Grazia Daidone, Alessandro M. Gianni, Roberto Salvioni
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: neoadjuvant chemotherapy, muscle-invasive bladder cancer, urothelial carcinoma, sorafenib, cisplatin, gemcitabine, pathological complete response, radical cystectomy, vascular endothelial growth factor, circulating tumor cells, biomarkers, hand-foot syndrome, hematologic toxicity, treatment toxicity, disease-free survival, recurrence-free survival, progression-free survival
Open Access status: closed
OpenAlex ID: W2591076216
